- Acquisition adds potential novel oral peptide IL23R
inhibitor for psoriasis as well as a peptide synthesis, screening
and optimization platform to strengthen AbbVie's pipeline and
R&D capabilities
NORTH
CHICAGO, Ill., Jan. 23,
2025 /PRNewswire/ -- AbbVie (NYSE: ABBV)
announced today that it has completed its acquisition of Nimble
Therapeutics. With the completion of the acquisition, Nimble is now
a part of AbbVie.
Nimble's lead asset is an investigational oral peptide IL23R
inhibitor in preclinical development for the treatment of
psoriasis. Additionally, Nimble's peptide synthesis, screening, and
optimization platform uses proprietary technology to help drive
rapid discovery and optimization of oral peptide candidates for a
range of targets.
"With the acquisition now complete, we are excited to expand our
immunology pipeline to include Nimble's novel oral peptide assets
and look forward to integrating this proprietary technology into
our R&D capabilities," said Jonathon
Sedgwick, Ph.D., senior vice president and global head of
discovery research, AbbVie. "We are pleased to welcome the talented
team at Nimble who share our commitment to elevating the standard
of care for people living with autoimmune diseases."
For additional background on the acquisition, please read the
announcement press release here.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-nimble-therapeutics-302358709.html
SOURCE AbbVie
